Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Insmed Inc (INSM)

Insmed Inc (INSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,278,456
  • Shares Outstanding, K 101,868
  • Annual Sales, $ 136,470 K
  • Annual Income, $ -254,340 K
  • 60-Month Beta 2.43
  • Price/Sales 23.50
  • Price/Cash Flow N/A
  • Price/Book 12.01
Trade INSM with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.67
  • Number of Estimates 6
  • High Estimate -0.54
  • Low Estimate -0.79
  • Prior Year -0.59
  • Growth Rate Est. (year over year) -13.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.71 +30.45%
on 01/11/21
43.58 -2.09%
on 01/25/21
+7.26 (+20.50%)
since 12/24/20
3-Month
30.03 +42.09%
on 11/02/20
43.58 -2.09%
on 01/25/21
+5.68 (+15.36%)
since 10/23/20
52-Week
12.09 +252.94%
on 03/17/20
43.58 -2.09%
on 01/25/21
+22.58 (+112.39%)
since 01/24/20

Most Recent Stories

More News
Lobe Sciences Announces Management Changes and New Director

Vancouver, British Columbia--(Newsfile Corp. - January 18, 2021) -  Lobe Sciences Ltd (CSE: LOBE) (OTC Pink: GTSIF) ("" or the "") is pleased to announce the appointment of Mr. Philip J. Young as Chief...

APHB : 0.32 (-20.33%)
EXDI : 0.1500 (-6.25%)
INSM : 43.15 (+2.74%)
LOBE.CN : 0.125 (-3.85%)
GTSIF : 0.1000 (-2.53%)
Insmed to Present at the 39th Annual J.P. Morgan Healthcare Conference

, /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management...

JPM : 131.08 (-2.03%)
INSM : 43.15 (+2.74%)
Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease

, /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the first...

INSM : 43.15 (+2.74%)
Insmed Inc Set to Possibly Rebound After Yesterday's Selloff of 1.02%

Insmed Inc (NASDAQ:INSM) traded in a range yesterday that spanned from a low of $34.70 to a high of $35.53. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $35.15...

INSM : 43.15 (+2.74%)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

, /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of...

INSM : 43.15 (+2.74%)
Insmed (INSM) Starts Dosing in Phase III Bronchiectasis Study

Insmed (INSM) doses the first patient in the phase III ASPEN study evaluating its pipeline candidate brensocatib for the treatment of patients with bronchiectasis.

HALO : 48.03 (-2.97%)
INSM : 43.15 (+2.74%)
CBIO : 6.75 (-1.60%)
APTO : 4.30 (-2.05%)
Insmed Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

, /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the first patient...

INSM : 43.15 (+2.74%)
Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference

, /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management...

INSM : 43.15 (+2.74%)
Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

, /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the European...

INSM : 43.15 (+2.74%)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

, /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of...

INSM : 43.15 (+2.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas...

See More

Key Turning Points

3rd Resistance Point 44.56
2nd Resistance Point 43.38
1st Resistance Point 42.69
Last Price 43.15
1st Support Level 40.82
2nd Support Level 39.64
3rd Support Level 38.95

See More

52-Week High 43.58
Last Price 43.15
Fibonacci 61.8% 31.55
Fibonacci 50% 27.84
Fibonacci 38.2% 24.12
52-Week Low 12.09

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar